Table 1 Dose Reduction Index values for the drugs combination at 30%, 50%, 70% and 90% levels of inhibition of Toledo, OCI-LY3 and SU-DHL10 cell viability after 144 h of metronomic vinorelbine (VNR) or etoposide (ETO) plus tafasitamab (TAFA) concomitant combination treatment.
Fraction affected | DRI values | |||||
|---|---|---|---|---|---|---|
Toledo | OCI-LY3 | SU-DHL10 | ||||
VNR | TAFA | VNR | TAFA | VNR | TAFA | |
30% | 1.6 | 3.1 | 1.09 | 14.7 | 90.5 | 2.4 |
50% | 1.4 | 7.5 | 1.4 | 15.4 | 37.2 | 4.5 |
70% | 1.3 | 18.2 | 1.8 | 16.2 | 15.3 | 8.6 |
90% | 1.04 | 74.4 | 2.7 | 17.5 | 3.7 | 23.7 |
ETO | TAFA | ETO | TAFA | ETO | TAFA | |
|---|---|---|---|---|---|---|
30% | 4079.6 | 7463.2 | 21.2 | 766.2 | 1.4 | 0.05 |
50% | 801.7 | 3712.6 | 110.6 | 842.7 | 1.6 | 0.22 |
70% | 157.5 | 1846.9 | 577.3 | 926.9 | 1.7 | 0.99 |
90% | 11.8 | 607.2 | 8028.7 | 1078.6 | 2.1 | 11.21 |
